Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation

Stroke

Volumn 28, Issue 5, 1997, Pages 1015-1021

  Morocutti, Cristoforo ^e   Amabile, Giuseppe ^f   Fattapposta, Francesco ^f   Nicolosi, Alfredo ^a   Matteoli, Sergio ^b   Trappolini, Massimo ^b   Cataldo, Gabriella ^c   Milanesi, Geremia ^f   Lavezzari, Maurizio ^d   Pamparana, Franco ^d   Coccheri, Sergio ^f  

^a Ist Tecnologie Biomediche A   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d PFIZER INC   (United States)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f NONE

Author keywords

antiplatelet therapy; atrial fibrillation; thromboembolism; warfarin

Indexed keywords

INDOBUFEN; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 8244245263     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.28.5.1015     Document Type: Article

References (32)

1. Wolf PA, Dawber TR, Thomas E Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology. 1978;28:973-977.
2. Cerebral Embolism Task Force. Cardiogenic brain embolism. Arch Neurol. 1986;43:71-84.
3. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: a randomized trial. Stroke. 1983;14:668-676.
4. Cerebral Embolism Task Force. Cardiogenic brain embolism, second report. Arch Neurol. 1989;46:727-743.
5. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
6. Mannucci L, Maderna W, Colli S, Lavezzari M, Sirtori CR, Tremoli E. Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk. Thromb Res. 1987;48: 417-426.
7. Cattaneo M, Bevilacqua C, Lecchi A, Mannucci PM. In vitro and ex vivo effects of indobufen on human platelet aggregation, the release reaction and thromboxane B: production. Haemostasis. 1990;17: 293-300.
8. Crow MJ, Salter MCP, Donaldson DR, Rajah SM. Inhibition of platelet function with indobufen: correlation with plasma drug level. Thromb Res. 1985;38:303-306.
9. The SINBA Group. Indobufen versus aspirin plus dipyridamole after coronary artery bypass surgery. Coronary Artery Dis. 1991;2: 907-912.
10. Cataldo G, Braga M, Pirotta N, Lavezzari M, Rivelli F, Marubini E, on behalf of SINBA. Factors influencing 1-year patency of coronary artery saphenous vein graft. Circulation. 1993;88(pt 2):93-98.
11. Rajah SM, Nair U, Rees M, Saunders N, Walker D, Williams G, Critchley A, Beton D, Campbell C, Lawson RA, Rahman A, Nair KK, Dyet J, Kushwaha S, Reed A, Powell JD, Drake J. Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1994;107:1146-1153.
12. Fornaro G, Rossi P, Mantica PG, Caccia ME, Aralda D, Lavezzari M, Pamparana F, Milanesi G. Indobufen in the prevention of thromboembolic complications in patients with heart disease: a randomized, placebo-controlled, double-blind study. Circulation. 1993;87:162-164.
13. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. 2nd ed. Littleton, Mass: PGS Publishing Co; 1985.
14. Fleiss JL. Statistical Methods for Rales and Proportions. 2nd ed. New York, NY: John Wiley & Sons; 1981.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Cox DR. Regression models and life tables. J R Stat Soc B. 1972; 34:187-220.
17. Cox DR, Oakes D. Analysis of Survival Data. London, England: Chapman & Hall; 1984.
18. Dunnett CW, Gent M. Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables. Biometrics. 1977;33:593-602.
19. Blackwelder WC. 'Proving the null hypothesis' in clinical trials. Control Trials. 1982;3:345-353.
20. Min Lai S, Alter M, Friday G, Sobel E. A multifactorial analysis of risk factors for recurrence of ischemic stroke. Stroke. 1994;25: 958-962.
21. Van Latum JC, Koudstaal PJ, Venables GS, Van Gijn J, Kappelle LJ, Algra A, for the European Atrial Fibrillation Trial (EAFT) Study Group. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with non-rheumatic atrial fibrillation. Stroke. 1995;16:801-806.
22. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-638.
23. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Circulation. 1991;84:527-539.
24. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
25. Patrignani P, Ponara MR, Greco A, Fusco O, Natoli C, Iabolelli S, Cipollone F, Ganci A, Creminon C, Maclong J, Patrono C. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994;271:1705-1712.
26. Patrono C, Patrignani P, Rocca B, Landolfi R. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. Thromb Haemost. 1995;74:396-400.
27. Koudstaal PJ, Ciabattoni G, van Gijn J, Nieuwenhims HK, de Groot PG, Sixma JJ, Patrono C. Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke. 1993;24: 219-223.
28. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC, on behalf of the Stroke Prevention in Atrial Fibrillation Investigators. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Neurology. 1993;43:32-36.
29. Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med. 1995;332:238-248.
30. Cheng TO. Atrial fibrillation, stroke and antithrombotic treatment. Am Heart J. 1994;127:961-968.
31. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:5-10.
32. Hart RG, Coull BM, Hart D. Early recurrent embolism associated with non-valvular atrial fibrillation: a retrospective study. Stroke. 1983;14:448-693.